The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 |
doi: 10.3389/fgene.2024.1465318
This article is part of the Research Topic Genetic and Immunological Insights in Solid Tumors: Comprehensive Approaches to Treatment View all articles
Monocyte to High-density lipoprotein Ratio based Prognostic Nomogram for patients following Allogeneic Vascular Replacement Pancreaticoduodenectomy
Provisionally accepted- 1 Department of Nephrology, Wuhu Hospital, East China Normal University, Shanghai, Shanghai Municipality, China
- 2 Second People's Hospital of Wuhu, Wuhu, Anhui Province, China
- 3 Department of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Immune-inflammatory metabolic marker for PDAC 2 Background: Preoperative immune-inflammatory condition influencing the metabolism of malignancies. We sought to investigate the prognostic value of a novel immune-inflammatory metabolic marker, the monocyte-to-high-density lipoprotein ratio (MHR), in patients with locally advanced pancreatic cancer.A retrospective analysis was conducted on the clinical data of 118 patients with locally advanced pancreatic cancer and obstructive jaundice who underwent allogeneic vascular replacement pancreaticoduodenectomy in our hospital from Apr. 2011 to Dec. 2023. To assess the predictive capacity of immune-inflammatory metabolic marker, we utilized the area under the receiver operating characteristic curve (AUC-ROC) and assessed the predictive potential of MHR in forecasting outcomes through both univariate and multivariate Cox proportional hazard analyses.The area under AUC for MHR in predicting 1-year postoperative survival was 0.714, with an optimal cutoff value of 1.184, yielding a sensitivity of 78.9% and specificity of 66.2%.Based on this cutoff value, patients were divided into a low MHR group (MHR ≤ 1.184, n=61) and a high MHR group (MHR > 1.184, n=57). The median survival times for the low and high MHR groups were 27.0 months and 12.0 months, respectively (χ2=30.575, P<0.001), and the median DFS were 18.0 months and 8.0 months, respectively (χ2=26.330, P<0.001). Univariate and multivariate analyses indicated that preoperative MHR, preoperative creatinine, operation duration, and TNM stage were independent predictors of postoperative mortality, while preoperative MHR, preoperative creatinine, and TNM stage were independent predictors of postoperative recurrence risk.in patients with advanced PC after pancreaticoduodenectomy. Early monitoring and reduction of MHR may be of great significance in improving prognosis.
Keywords: Immune-inflammatory metabolic marker, monocyte to high-density lipoprotein ratio, Creatinine, Allogeneic vascular replacement, prognosis
Received: 16 Jul 2024; Accepted: 12 Aug 2024.
Copyright: © 2024 Ye, Wang, Shao, Tang, Dong and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaowen Ye, Department of Nephrology, Wuhu Hospital, East China Normal University, Shanghai, 200062, Shanghai Municipality, China
Yingchun Tang, Department of Nephrology, Wuhu Hospital, East China Normal University, Shanghai, 200062, Shanghai Municipality, China
Xiongjun Dong, Department of Nephrology, Wuhu Hospital, East China Normal University, Shanghai, 200062, Shanghai Municipality, China
Yaning Zhu, Department of Nephrology, Wuhu Hospital, East China Normal University, Shanghai, 200062, Shanghai Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.